CALCIMEDICA, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.597 USD | +1.40% |
|
-6.09% | +95.71% |
| 24/04 | Calcimedica Inc. Announces Last Patient Enrolled in Phase 2B Carpo Trial of Auxora? in Acute Pancreatitis | CI |
| 01/04 | Top Premarket Decliners | MT |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 16.26 | 60.12 | - | - |
| Enterprise Value (EV) 1 | 16.26 | 60.12 | 60.12 | 60.12 |
| P/E ratio | -0.37 x | -2.44 x | -2.54 x | -3.18 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | 21.5 x |
| EV / Revenue | - | - | - | 21.5 x |
| EV / EBITDA | -0.43 x | -2.31 x | -1.91 x | -1.9 x |
| EV / FCF | - | -1.94 x | -1.72 x | -1.4 x |
| FCF Yield | - | -51.6% | -58.2% | -71.5% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 5,685 | 10,740 | - | - |
| Reference price 2 | 2.860 | 5.597 | 5.597 | 5.597 |
| Announcement Date | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 2.8 |
| EBITDA 1 | - | - | -38.02 | -26 | -31.5 | -31.7 |
| EBIT 1 | - | - | -38.08 | -26.4 | -36.17 | -34.35 |
| Operating Margin | - | - | - | - | - | -1,226.79% |
| Earnings before Tax (EBT) 1 | - | - | -34.36 | -26 | -35.8 | -34.15 |
| Net income 1 | -23.5 | -14.51 | -34.36 | -26 | -35.8 | -34.15 |
| Net margin | - | - | - | - | - | -1,219.64% |
| EPS 2 | -8.650 | -5.080 | -7.660 | -2.290 | -2.203 | -1.760 |
| Free Cash Flow 1 | - | - | - | -31 | -35 | -43 |
| FCF margin | - | - | - | - | - | -1,535.71% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 20/01/23 | 04/04/23 | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | -4.3 | -5.1 | -5.9 | -6.8 | -8.3 |
| EBIT 1 | -22.34 | -6.583 | -4.833 | -4.319 | -7.4 | -7.1 | -5.75 | -6.35 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -19.29 | -6.304 | -4.619 | -4.146 | -6.6 | -6.333 | -6.1 | -6.967 |
| Net income 1 | -19.29 | -6.304 | -4.619 | -4.146 | -6.6 | -6.333 | -6.1 | -6.967 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -3.407 | -1.110 | -0.8200 | -0.2300 | -0.7400 | -0.5967 | -0.5133 | -0.5100 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 12/05/23 | 10/08/23 | 09/11/23 | 28/03/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -31 | -35 | -43 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 20/01/23 | 04/04/23 | 28/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.597
USD
Average target price
18.67
USD
Spread / Average Target
+233.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +95.71% | 60.12M | |
| +2.97% | 108B | |
| +10.21% | 105B | |
| +1.57% | 23.46B | |
| -12.77% | 21.72B | |
| -7.05% | 18.64B | |
| -37.64% | 17.45B | |
| -6.50% | 17.19B | |
| +6.00% | 13.99B | |
| +37.20% | 12.53B |
- Stock Market
- Equities
- CALC Stock
- Financials CalciMedica, Inc.